CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net income (loss)	$ (262,803)	$ (106,864)	$ (406,787)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	20,161	13,772	14,670
Stock-based compensation expense	69,495	28,381	292,394
Loss on debt extinguishment	0	0	1,590
Loss (income) from equity method investments	(16,489)	(10,720)	6,766
Deferred income taxes and uncertain tax positions	0	532	(3,231)
Release of indemnification assets	0	553	1,705
(Gain) loss on sale of assets, net	47,548	0	(473)
Distributions of earnings from equity method investments	0	0	174
Other non-cash items	(4,044)	2,973	58
Changes in operating assets and liabilities:
Receivables, net	(460,365)	(204,167)	(149,041)
Prepaid expense and other current assets	(6,120)	(16,620)	(3,916)
Other assets	(397)	(205)	3,931
Medical claims and related payables	441,500	107,713	76,339
Accounts payable and accrued expenses	32,111	65,736	19,360
Other liabilities	(16,796)	(11,892)	(1,698)
Net cash provided by (used in) operating activities	(156,199)	(130,808)	(148,159)
Cash flows from investing activities:
Purchase of property and equipment	(15,830)	(15,426)	(6,564)
Purchase of intangible assets	(14,985)	(17,235)	(6,862)
Investments in loans receivable and other	(19,528)	(6,510)	(82,831)
Investments in marketable securities	(114,657)	(458,265)	0
Proceeds from maturities and sales of marketable securities and other	164,040	52,548	7,095
Net cash paid in business combination	(45,252)	0	0
Proceeds from sale of business and property, net of cash divested	2,193	500	(1,344)
Net cash provided by (used in) investing activities	(44,019)	(444,388)	(90,506)
Cash flows from financing activities:
Proceeds from initial public offering	0	0	1,170,942
Proceeds from other equity issuances, net	11,867	33,056	18,086
Common stock repurchase	(200,000)	0	0
Proceeds from the issuance of long-term debt	0	0	100,000
Repayments of long-term borrowings and other	(5,000)	(5,000)	(119,899)
Equity and debt issuance costs and other	0	0	(14,739)
Net cash provided by (used in) financing activities	(193,133)	28,056	1,154,390
Net increase (decrease) in cash, cash equivalents and restricted cash and equivalents	(393,351)	(547,140)	915,725
Cash, cash equivalents and restricted cash and equivalents from continuing operations, beginning of year	475,912	1,049,373	128,201
Cash, cash equivalents and restricted cash and equivalents from discontinued operations, beginning of year	31,768	5,447	10,894
Cash, cash equivalents and restricted cash and equivalents, beginning of year	507,680	1,054,820	139,095
Cash, cash equivalents and restricted cash and equivalents from continuing operations, end of year	114,329	475,912	1,049,373
Cash, cash equivalents and restricted cash and equivalents from discontinued operations, end of year	0	31,768	5,447
Cash, cash equivalents and restricted cash and equivalents, end of year	$ 114,329	$ 507,680	$ 1,054,820